Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYMAKER-U06 Substudy 06F in previously treated advanced esophageal squamous cell carcinoma
jRCT2041250179Recruiting
- Sponsor
- Merck & Co.
- Start
- Apr 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Trial of ifinatamab deruxtecan, sponsored by Merck & Co. Started Apr 2026; status: recruiting.
02
Drugs
ifinatamab deruxtecan
Beyond the preview
Go deeper on jRCT2041250179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041250179.